RA0696

antibody from Oursmab

Targeting: SNCA NACP, PARK1, PARK4, PD1

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0696

Provider

Oursmab

Product name

Exidavnemab (Biosimilar Reference Antibody) (SNCA)

Antibody type

Monoclonal

Description

Exidavnemab is an investigational monoclonal antibody being developed as a novel disease-modifying treatment for neuronal synucleinopathies, specifically Multiple System Atrophy (MSA) and Parkinson's disease (PD). It functions as a targeted immunotherapeutic agent designed to engage with and promote the clearance of pathological alpha-synuclein (¦Á-synuclein) aggregates, a hallmark proteinopathy central to these neurodegenerative diseases. By binding to specific forms of misfolded ¦Á-synuclein, exidavnemab aims to facilitate their removal, potentially slowing or halting the underlying neurodegenerative process, rather than merely alleviating symptoms.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.